46 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
28 Mar 24
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
7:45am
December 31, 2023
Research and Development Service Revenue, related party: Research and development service revenue, related party, for each of the quarter … and Development Expenses: Research and development expenses were $7.3 million for the fourth quarter of 2023 compared to $5.0 million for the fourth
8-K
EX-99.1
CADL
Candel Therapeutics Inc
9 Nov 23
Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
8:16am
2024.
Financial Results for the Quarter Ended September 30, 2023
Research and Development Service Revenue, related party: Research and development … million up-front license fee that Candel received in 2014 and 2015 from Ventagen LLC was fully recognized as of December 2022.
Research and Development
8-K
EX-99.1
h8i76tbxx7a2 qi48j2
10 Aug 23
Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
8:15am
8-K
EX-99.1
wcb4d
8 Jun 23
Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors
8:15am
8-K
EX-99.1
rjw9e
11 May 23
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
8:31am
8-K
EX-99.1
iokf0 xc4wi
30 Mar 23
Candel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Highlights
8:30am
8-K
EX-99.1
k9wh 8us5ln7
6 Dec 22
Other Events
5:30pm
8-K
zcss2421px
6 Dec 22
Other Events
5:30pm
8-K
cbsd8n
6 Dec 22
Regulation FD Disclosure
8:01am
8-K
EX-99.1
dt13n
6 Dec 22
Regulation FD Disclosure
8:01am
8-K
p3xt zt49u3vjwsw
29 Nov 22
Regulation FD Disclosure
8:31am
8-K
EX-99.1
73k0kx9bzbj
29 Nov 22
Regulation FD Disclosure
8:31am
8-K
EX-99.1
2imr4v2ec gp
10 Nov 22
Candel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
8:30am